S1PR1 and myeloid sarcoma: Ponesimod is a highly selective S1PR1 antagonist with S1PR5 antagonistic activity and is currently approved for the treatment of MS in the United States, the European Union, and the United Kingdom (Rasche and Paul, 2018).